FirebrickPharma

21 November 2025

ASX Announcement

Notice of Change of Auditor

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) advises that the Australian Securities and Investments Commission (ASIC) have consented to the resignation of the Company's auditor, BDO Audit Pty Ltd, effective from 1 December 2025.

In accordance with ASIC Regulatory Guide 26, paragraphs RG 26.59-RG 26.61, the Company provides the following information:

The outgoing auditor is:	BDO Audit Pty Ltd
	Level 9, Mia Yellagonga Tower 2, 5 Spring St, Perth WA 6000
The incoming auditor is:	Criterion Audit Pty Ltd
	Suite 2, 642 Newcastle Street, Leederville WA 6007

The reason for the change of auditor is to align our audit services with the size and nature of the business, which will result in cost reductions.

The Company will table a resolution seeking to ratify the appointment of Criterion Audit Pty Ltd at the Company's next Annual General Meeting to be held around November 2026.

This announcement was authorised for release by the Board of Firebrick Pharma.

- ENDS -

About Firebrick (ASX:FRE)
Firebrick Pharma is a pharmaceutical innovator developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine® Nasal Spray (0.5% PVP-I). Firebrick has already introduced Nasodine Nasal Spray into the United States, Singapore and Fiji & South Pacific, with approval in the Philippines expected in 2026. Firebrick also recently announced the successful development and upcoming launch in Singapore of its first new product, Nasodine Throat Spray.

Media enquiries:
Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:
Investors@firebrickpharma.com